[{"id":"e41a0274-04d0-4274-aa51-19e90a49274f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983954","created_at":"2021-01-18T19:35:39.578Z","updated_at":"2025-02-25T15:08:38.440Z","phase":"Phase 1","brief_title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03983954","lead_sponsor":"NeoTX Therapeutics Ltd.","biomarkers":" HER-2 • ER • TPBG","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • TPBG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-22"}]